Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP518166.RA9n0u-4w51jGEpNIav_oGDPro7SeCw1C9TcBEp3AYU34130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP518166.RA9n0u-4w51jGEpNIav_oGDPro7SeCw1C9TcBEp3AYU34130_assertion type Assertion NP518166.RA9n0u-4w51jGEpNIav_oGDPro7SeCw1C9TcBEp3AYU34130_head.
- NP518166.RA9n0u-4w51jGEpNIav_oGDPro7SeCw1C9TcBEp3AYU34130_assertion description "[The Mdm2 inhibitor nutlin-3 was evaluated alone and in combination with cisplatin in a panel of germ cell tumour (GCT)-derived cell lines (embryonal carcinomas, being the nonseminomatous stem-cell component) with wild-type (NT2 and 2102EP cells) and mutant (NCCIT cells) p53 status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP518166.RA9n0u-4w51jGEpNIav_oGDPro7SeCw1C9TcBEp3AYU34130_provenance.
- NP518166.RA9n0u-4w51jGEpNIav_oGDPro7SeCw1C9TcBEp3AYU34130_assertion evidence source_evidence_literature NP518166.RA9n0u-4w51jGEpNIav_oGDPro7SeCw1C9TcBEp3AYU34130_provenance.
- NP518166.RA9n0u-4w51jGEpNIav_oGDPro7SeCw1C9TcBEp3AYU34130_assertion SIO_000772 19560254 NP518166.RA9n0u-4w51jGEpNIav_oGDPro7SeCw1C9TcBEp3AYU34130_provenance.
- NP518166.RA9n0u-4w51jGEpNIav_oGDPro7SeCw1C9TcBEp3AYU34130_assertion wasDerivedFrom befree-20140225 NP518166.RA9n0u-4w51jGEpNIav_oGDPro7SeCw1C9TcBEp3AYU34130_provenance.
- NP518166.RA9n0u-4w51jGEpNIav_oGDPro7SeCw1C9TcBEp3AYU34130_assertion wasGeneratedBy ECO_0000203 NP518166.RA9n0u-4w51jGEpNIav_oGDPro7SeCw1C9TcBEp3AYU34130_provenance.